Here are 1-2 brief analogies for Agios Pharmaceuticals (AGIO):

• Vertex Pharmaceuticals for rare genetic blood disorders.
• Sarepta Therapeutics, but for rare metabolic and blood disorders.

• Pyrukynd (mitapivat): An oral medication approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
• AG-946: An investigational oral pan-PKR activator currently in clinical development for various anemias.
• AGT-001: An investigational oral activator of phenylalanine hydroxylase (PAH) in clinical development for phenylketonuria (PKU).

Agios Pharmaceuticals (AGIO) is a biotechnology company that develops and commercializes therapies for rare and genetically defined diseases. Its primary commercial product is PYRUKYND® (mitapivat). Like most pharmaceutical manufacturers, Agios sells its commercialized products primarily to other companies, specifically wholesale pharmaceutical distributors and specialty pharmacies. These entities then distribute the products to hospitals, clinics, and retail pharmacies, which ultimately dispense them to individual patients.

Therefore, Agios's major customers are other companies. Based on typical industry sales channels and reported sales concentrations by pharmaceutical companies, the following are generally considered the major wholesale distributors in the U.S. and are highly likely to be Agios's primary customers for PYRUKYND®:

• McKesson Corporation (NYSE: MCK)
• AmerisourceBergen Corporation (NYSE: ABC)
• Cardinal Health, Inc. (NYSE: CAH)

null

Brian Goff, Chief Executive Officer

Brian Goff joined Agios as Chief Executive Officer and a member of its board of directors in August 2022. He brings over 30 years of experience in the biopharmaceutical industry, with the last 10 years focused on rare diseases. Prior to Agios, he served as executive vice president, chief commercial and global operations officer of Alexion Pharmaceuticals until its acquisition by AstraZeneca in 2021. Before Alexion, he was chief operating officer and a board member of Neurovance, a venture-backed company acquired by Otsuka Pharmaceuticals in 2017. He also served as Baxalta's executive vice president and president of the hematology division until Shire Pharmaceuticals acquired Baxalta in 2016. Earlier in his career, Mr. Goff held positions at Novartis Pharmaceuticals and spent nearly 14 years in the pharmaceutical division of Johnson & Johnson.

Cecilia Jones, Chief Financial Officer

Cecilia Jones was appointed Chief Financial Officer of Agios in September 2022. She has more than 20 years of financial experience within the biopharmaceutical industry, including several companies focused on rare diseases. Before joining Agios, she served as chief financial officer at LogicBio Therapeutics. Prior to LogicBio, Ms. Jones spent over 10 years at Biogen in roles of increasing responsibility within the finance organization, including vice president of R&D, worldwide medical and business development finance. She also served as director of international finance at Genzyme. Her expertise includes driving financial strategy, evaluating financing alternatives, and analyzing business development and M&A opportunities.

Jacqualyn A. Fouse, Ph.D., Chairman of the Board

Dr. Jacqualyn Fouse transitioned to Chairman of the Board in August 2022, after serving as CEO of Agios Pharmaceuticals since 2019. She led the company's strategic pivot to focus on genetically defined diseases, which included the $1.8 billion sale of its oncology portfolio in April 2021.

Sarah Gheuens, M.D., Ph.D., Chief Medical Officer and Head of Research & Development

Dr. Sarah Gheuens serves as the Chief Medical Officer and Head of Research & Development at Agios Pharmaceuticals.

James Burns, Corporate Secretary & Chief Legal Officer

James Burns is the Corporate Secretary & Chief Legal Officer at Agios Pharmaceuticals.

The key risks to Agios Pharmaceuticals (AGIO) are primarily centered around regulatory and clinical development, competitive pressures, and ongoing profitability challenges.

1. Regulatory and Clinical Development Risk: Agios Pharmaceuticals faces significant risk concerning the regulatory approval and clinical development of its lead product, PYRUKYND (mitapivat). The company is awaiting crucial FDA decisions for label expansion in thalassemia, and there have been recent delays in the Prescription Drug User Fee Act (PDUFA) goal date due to requests for a Risk Evaluation and Mitigation Strategy (REMS) to address potential liver toxicity concerns. While these delays are viewed by some as procedural, a negative decision or restrictive labeling could significantly impact the drug's market potential and future revenue streams. Furthermore, recent Phase 3 results for mitapivat in sickle cell disease (SCD) were mixed, meeting the primary hemoglobin endpoint but not showing statistical significance in reducing pain crises or improving fatigue, which could raise doubts about its real-world efficacy and future approvals in that indication. The success of these upcoming regulatory rulings and trial results is considered "make-or-break" for the company's investment case.
2. Competition: Agios operates in a competitive landscape, facing rivals developing gene therapies and next-generation small molecules for rare blood diseases, including thalassemia and sickle cell disease. Competitors such as PTC Therapeutics, Praxis Precision Medicines, CRISPR Therapeutics, and others are actively working in the pharmaceutical products industry. The emergence of potentially curative gene therapies from larger, well-funded competitors poses a significant external threat, as these could capture market share in areas Agios is targeting.
3. High Cash Burn and Profitability Concerns: Agios Pharmaceuticals is currently not profitable, exhibiting a high cash burn rate with an operating margin significantly in the negative and substantial free cash flow yield in the red. The company incurs considerable expenses in research and development (R&D) and selling, general, and administrative (SG&A) costs. While Agios maintains a strong cash position, continued high cash burn without significant revenue generation from new approvals could necessitate dilutive fundraising, thereby eroding shareholder value. The ability to scale commercial operations for potential new indications like thalassemia and SCD will be crucial to overcoming these profitability challenges.

The emergence and approval of gene therapies for beta-thalassemia and sickle cell disease pose a significant threat. Agios Pharmaceuticals is developing mitapivat, a chronic oral therapy, for these same indications (currently in Phase 3 for beta-thalassemia and Phase 2/3 for sickle cell disease). However, companies like Vertex/CRISPR Therapeutics (Casgevy) and bluebird bio (Lyfgenia, Zynteglo) have already received regulatory approvals for one-time, potentially curative gene therapies for these conditions. The availability of these transformative treatments fundamentally changes the treatment paradigm, potentially diminishing the future market opportunity and adoption for chronic management therapies like mitapivat in these areas, even if mitapivat demonstrates efficacy.

Agios Pharmaceuticals (AGIO) is poised for significant revenue growth over the next 2-3 years, driven by the expansion of its flagship product PYRUKYND into new indications, continued uptake in its existing market, and the progression of its pipeline.

Here are 3-5 expected drivers of future revenue growth:

• Expansion of PYRUKYND into Thalassemia: Agios anticipates a substantial increase in revenue from the potential U.S. approval and commercial launch of PYRUKYND for adult patients with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. The FDA accepted the supplemental New Drug Application (sNDA) with a Prescription Drug User Fee Act (PDUFA) goal date extended to December 7, 2025. Beyond the U.S., regulatory filings are also progressing in Europe, Saudi Arabia, and the United Arab Emirates, setting the stage for global market penetration in this indication.
• Launch of PYRUKYND for Sickle Cell Disease (SCD): A major growth catalyst is the expected U.S. commercial launch of PYRUKYND for sickle cell disease in 2026. Topline results from the Phase 3 RISE UP study of mitapivat in SCD are anticipated in late 2025. If successful, this would position PYRUKYND as a critical therapy in another large, underserved patient population.
• Continued Growth of PYRUKYND in Pyruvate Kinase Deficiency (PKD): Agios has demonstrated robust performance in its existing market, with net PYRUKYND revenue showing strong year-over-year increases. The company continues to see consistent growth in its patient base for pyruvate kinase deficiency, contributing to ongoing revenue.
• Advancement of Tebapivat for Lower-Risk Myelodysplastic Syndromes (LR-MDS): The progression of tebapivat, another pyruvate kinase activator, for lower-risk myelodysplastic syndromes represents a potential future revenue stream. Patient enrollment for the Phase 2b study is expected to be completed in late 2025.
• Development of Early-Stage Pipeline Assets: Agios is also investing in its early-stage pipeline, including AG-236, a siRNA targeting TMPRSS6 for the treatment of polycythemia vera. The company plans to file an Investigational New Drug (IND) application for AG-236 in mid-2025, laying the groundwork for long-term growth and diversification of its product portfolio.

Share Repurchases

• In March 2021, Agios Pharmaceuticals authorized a share repurchase program of up to $1.2 billion following the sale of its oncology business.
• As part of this program, on March 31, 2021, Agios repurchased 7,121,658 shares of its common stock from Bristol-Myers Squibb (BMS) for approximately $344.5 million.

Share Issuance

• Agios has reported that shares outstanding have remained relatively stable, with minor equity issuances providing some additional capital and limited dilution over time.

Inbound Investments

• In December 2020, Agios entered an agreement to sell its oncology business to Servier for $1.8 billion in cash at closing, with potential for an additional $200 million milestone payment and royalties.
• In June 2020, the company sold its tiered royalty rights on worldwide net sales of IDHIFA® to Royalty Pharma for $255 million, including potential regulatory milestone payments of up to $55 million.
• A net income of $947.9 million in the third quarter of 2024 was primarily attributed to a milestone payment from Servier and the sale of royalty rights to Royalty Pharma.

Capital Expenditures

• Capital expenditures for the last 12 months were approximately $4.16 million.
• The company is making significant investments in research and development (R&D) and selling, general, and administrative (SG&A) expenses, driven by increased clinical trial costs for its PK activation franchise and commercial preparations for potential new product launches such as PYRUKYND® in thalassemia.
• Agios anticipates that its cash, cash equivalents, and marketable securities will provide financial independence to support potential PYRUKYND® launches in thalassemia and sickle cell disease, advance existing programs, and explore pipeline expansion through internal and external assets, with a cash runway expected to extend at least into 2026.